Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

Published:2015-06 Issue:6 Volume:15 Page:645-653
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Mizokami Masashi,Yokosuka Osamu,Takehara Tetsuo,Sakamoto Naoya,Korenaga Masaaki,Mochizuki Hitoshi,Nakane Kunio,Enomoto Hirayuki,Ikeda Fusao,Yanase Mikio,Toyoda Hidenori,Genda Takuya,Umemura Takeji,Yatsuhashi Hiroshi,Ide Tatsuya,Toda Nobuo,Nirei Kazushige,Ueno Yoshiyuki,Nishigaki Yoichi,Betular Juan,Gao Bing,Ishizaki Akinobu,Omote Masa,Mo Hongmei,Garrison Kim,Pang Phillip S,Knox Steven J,Symonds William T,McHutchison John G,Izumi Namiki,Omata Masao

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference15 articles.

1. Changing trends in hepatitis C infection over the past 50 years in Japan;Chung;Intervirology,2010

2. JSH Guidelines for the Management of Hepatitis C Virus Infection: a 2014 update for genotype 1;Hepatol Res,2014

3. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial;Hayashi;J Hepatol,2014

4. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies;Izumi;J Gastroenterol,2014

5. Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study;Kumada;Hepatol Res,2014

Cited by 323 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial: Pathogen-host interaction in the development of viral hepatitis;Frontiers in Cellular and Infection Microbiology;2023-11-21

2. Recent Advances in the Pathogenesis and Clinical Evaluation of Portal Hypertension in Chronic Liver Disease;Gut and Liver;2023-10-16

3. Direct‑acting antiviral treatment is safe and effective for chronic HCV patients with psychiatric disorders;Experimental and Therapeutic Medicine;2023-07-07

4. Simple new clinical score to predict hepatocellular carcinoma after sustained viral response with direct-acting antivirals;Scientific Reports;2023-06-02

5. Hepatitis C Virus (HCV)-Ribonucleic Acid (RNA) As a Biomarker for Lymphoid Malignancy with HCV Infection;Cancers;2023-05-21